Mizuho initiated coverage of Vigil Neuroscience with a Buy rating and $15 price target. While the analyst noted that the company is an early-stage story, the firm has enthusiasm for the company’s immuno-neurology-based approach, the lack of current direct competition, increased FDA/regulatory embracing of biomarker-based approaches for NDG disease, and the potential for accelerated clinical development timelines.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VIGL:
- Vigil Neuroscience announces FDA lifts partial clinical hold on VGL101
- Vigil Neuroscience to Present at Stifel 2023 CNS Days
- Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Vigil Neuroscience reports Q4 EPS (48c), consensus (58c)
- Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting